KIMBERLEY MANGUS: Open Payments
NPI 1275075848 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,555 in 71 payments from 19 companies in 2025. Trend: 2023 $1,636 · 2024 $1,357 · 2025 $1,555
Food & beverage: $1,555
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 13 | $262 |
| BridgeBio Pharma, Inc. | 3 | $175 |
| Novartis Pharmaceuticals Corporation | 7 | $134 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $115 |
| Novo Nordisk Inc | 4 | $96 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 6 | $93 |
| E.R. Squibb & Sons, L.L.C. | 5 | $90 |
| SCPHARMACEUTICALS INC. | 5 | $89 |
| Merck Sharp & Dohme LLC | 4 | $80 |
| Boston Scientific Corporation | 3 | $71 |
Products named: ELIQUIS, Attruby, JARDIANCE, Wegovy, LEQVIO, LifeVest, CAMZYOS, FUROSCIX.
Industry payments across MD — which companies pay providers there.
